Market Overview

Needham Initiates Medtronic At Buy

Related MDT
Earnings Scheduled For February 21, 2017
DexCom Jumps 25% As It Becomes Only Continuous Glucose Monitoring With Medicare Coverage
Can 20 Financial Ratios Measure A Company's Moat Just Like Morningstar? Update (Seeking Alpha)

Analysts at Needham initiated coverage on shares of Medtronic (NYSE: MDT) with a Buy rating.

The target price for Medtronic is set to $74.

Medtronic shares have climbed 16.85% over the past 52 weeks, while the S&P 500 index has jumped 16.68% in the same period.

Medtronic's shares fell 1.26% to close at $62.54 yesterday.

Latest Ratings for MDT

Jan 2017Morgan StanleyDowngradesOverweightEqual-Weight
Jan 2017JP MorganDowngradesOverweightNeutral
Nov 2016BarclaysMaintainsOverweight

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: NeedhamInitiation Analyst Ratings


Related Articles (MDT)

View Comments and Join the Discussion!